Condition
Extramammary Paget Disease
Total Trials
5
Recruiting
3
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Recruiting3
Active Not Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT02834013Phase 2Active Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02978625Phase 2Active Not Recruiting
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT03564483Recruiting
Gynecologic Extramammary Paget's Disease
NCT05859074Phase 1Recruiting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
NCT07117851Phase 2RecruitingPrimary
A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Showing all 5 trials